Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (NYSE: ABBV) is a pharmaceutical preparation manufacturing company that regularly issues news on its medicines, research programs, collaborations and manufacturing plans. Company communications emphasize a mission to discover and deliver medicines and solutions in key therapeutic areas such as immunology, oncology, neuroscience and eye care, as well as offerings in its Allergan Aesthetics portfolio.
News about AbbVie often covers clinical and scientific developments, particularly in oncology and blood cancers. The company has reported new data at major medical meetings, including results for investigational agents like etentamig (ABBV‑383) and PVEK, and updates on approved medicines such as EPKINLY (epcoritamab-bysp) and VENCLEXTA (venetoclax). Releases may detail trial outcomes, regulatory milestones, and additional indications under investigation.
Investors and observers can also find corporate and financial updates in AbbVie’s news flow, including announcements of earnings conference calls, participation in healthcare and investor conferences, and guidance-related information that aligns with its SEC filings. The company additionally highlights strategic agreements and collaborations, such as its exclusive licensing agreement with RemeGen for the PD‑1/VEGF bispecific antibody RC148 and its voluntary agreement with the U.S. administration focused on access, affordability and U.S.-based investment.
Another recurring theme in AbbVie’s news is manufacturing and investment activity. The company has announced a definitive agreement to acquire a device manufacturing facility in Tempe, Arizona, to expand drug delivery device manufacturing for immunology and neuroscience medicines, and has referenced multi‑year commitments to U.S. R&D and capital investments. AbbVie also publishes stories on patient- and community-focused initiatives, such as the “Second Winds” film about people living with chronic lymphocytic leukemia. For readers tracking ABBV, this news stream provides insight into the company’s research pipeline, regulatory progress, capital allocation and patient engagement efforts.
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has secured a supplier agreement with Vizient, Inc., the largest provider-driven healthcare performance improvement company in the U.S. The agreement provides Vizient's network, which represents over 50% of U.S. healthcare organizations, enhanced access to Natrelle®'s comprehensive breast implant line featuring more than 300 implant options.
The partnership offers Vizient clients competitive pricing, simplified procurement, improved operational efficiency, and direct support from Natrelle®'s sales and technical teams. Natrelle®, currently the #1 selected breast implant by plastic surgeons, brings a 50-year legacy of excellence in breast reconstruction and augmentation solutions.
AbbVie (NYSE:ABBV) has initiated construction on a $70 million expansion at its AbbVie Bioresearch Center in Worcester, Massachusetts. The expansion is part of AbbVie's broader $10 billion U.S. investment commitment to enhance biologics manufacturing capabilities and capacity.
The project includes new biologics manufacturing areas and a three-story building for laboratory, warehouse, and office space. This investment will facilitate the transfer of select oncology products from Europe to the U.S. and support the production of current and next-generation oncology and immunology medicines. The expansion will create new jobs, adding to AbbVie's existing 28,000 U.S. employees, including over 2,000 in Massachusetts.
AbbVie (NYSE:ABBV) has submitted a Biologics License Application (BLA) to the FDA for Pivekimab sunirine (PVEK), a novel CD123-targeting antibody-drug conjugate designed to treat Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), a rare and aggressive blood cancer.
The BLA submission is supported by data from the Phase 1/2 CADENZA trial, which evaluated PVEK's safety and efficacy in BPDCN patients. This represents AbbVie's first ADC development in blood cancer, targeting the CD123 protein that is overexpressed in BPDCN cells.
BPDCN typically manifests with skin lesions and can spread to bone marrow, central nervous system, and lymph nodes. Current treatment options are limited to intensive chemotherapy and stem cell transplant, highlighting the urgent need for innovative therapies.
AbbVie (NYSE: ABBV) has commenced construction of a new active pharmaceutical ingredient (API) manufacturing facility in North Chicago, Illinois. The $195 million investment is part of AbbVie's broader $10 billion capital investment plan over the next decade to enhance U.S. manufacturing capabilities.
The facility, expected to be fully operational by 2027, will focus on producing API components for immunology, oncology, and neuroscience medicines. This strategic move will relocate select API production from Europe and Asia to the U.S. The project will create new jobs, adding to AbbVie's existing workforce of 28,000 U.S. employees across all 50 states and Puerto Rico, including 6,000 jobs at 11 manufacturing sites.
AbbVie (NYSE:ABBV) has announced its pricing strategy for ELAHERE® (mirvetuximab soravtansine-gynx) in the UK, setting the list price equal to US levels. ELAHERE is the first-and-only approved FRα-directed antibody drug conjugate (ADC) for treating platinum-resistant ovarian cancer patients who have received 1-3 prior treatments.
The company is currently in discussions with NICE to ensure fair valuation of ELAHERE, which represents the first new treatment in 10 years for platinum-resistant ovarian cancer in the UK. The drug received MHRA approval in July 2025, following FDA approval in March 2024 and European Commission approval in November 2024.
AbbVie (NYSE:ABBV) has submitted a New Drug Application (NDA) to the FDA for tavapadon, a novel once-daily oral treatment for Parkinson's disease. The submission is supported by positive results from the Phase 3 TEMPO clinical program, which demonstrated significant efficacy across multiple trials.
The TEMPO program included three Phase 3 trials: TEMPO-1 and TEMPO-2 showed statistically significant improvement in MDS-UPDRS Parts II and III scores in early Parkinson's patients, while TEMPO-3 demonstrated increased "on" time in patients using tavapadon as an adjunctive therapy to levodopa. The submission also includes interim data from the TEMPO-4 open-label extension trial.
Allergan Aesthetics (NYSE:ABBV) will showcase its new AA Signature™ multimodal treatment approach at the AMWC Dubai conference from October 1-3, 2025. The approach, already successfully launched in 25 countries, addresses different patient needs including Lift Up, Distinct Definition, and skin quality improvement.
The company will host two major symposiums: an AMI symposium featuring Dr. Mauricio de Maio demonstrating live injections, and a Global Medical Affairs symposium focused on skin quality multimodal mastery. Additionally, 7 e-posters presenting new clinical data will be featured at the conference, covering topics from personalized aesthetics to skin quality treatments.
Allergan Aesthetics (NYSE:ABBV) announced the expansion of SKINVIVE by JUVÉDERM® into 35 additional markets, bringing the total to 57 global markets in 2025. SKINVIVE® is positioned as the market's longest-lasting hydrating injectable, delivered in a single treatment.
The expansion aligns with growing market demand, as research shows 94% of people desire improved facial skin quality. The global skin quality market is valued at $5.2B, with consumers increasingly prioritizing skin health and natural-looking results. The company's AA Signature™ holistic approach has already launched in 25 countries, supporting this strategic expansion.
The announcement coincides with upcoming presentations at the Aesthetic Anti-Aging Medicine World Congress (AMWC) in Dubai on October 1, where experts will discuss integrated aesthetic modalities for skin quality improvement.
AbbVie's (NYSE:ABBV) subsidiary Allergan Aesthetics has launched its largest-ever marketing campaign for BOTOX® Cosmetic titled 'The One & Only.' The campaign showcases real patients and their unique stories across multiple media channels including TV, digital, and out-of-home advertising.
As the #1 selling neurotoxin worldwide, BOTOX® Cosmetic has achieved significant milestones with over 100 million vials sold globally and maintains the most FDA-approved aesthetic indication areas in its category. Market research indicates strong customer satisfaction, with 77% of treated consumers considering it worth the cost and 91% of patients expressing intent to continue treatment.
The product recently received recognition as 'Best Injectable' in the 2025 Cosmopolitan Readers' Choice Beauty Awards and continues to be the most trusted choice among aesthetic providers, with 95% of specialists choosing it for themselves, friends, and family.
AbbVie (NYSE:ABBV) has announced a quarterly cash dividend of $1.64 per share, payable on November 14, 2025, to stockholders of record as of October 15, 2025. The company has demonstrated strong commitment to shareholder returns, increasing its dividend by 310 percent since its inception in 2013.
As a member of the S&P Dividend Aristocrats Index, AbbVie has maintained a track record of consistently increasing its dividend for at least 25 consecutive years, highlighting its financial stability and dedication to shareholder value.
FAQ
What is the current stock price of Abbvie (ABBV)?
What is the market cap of Abbvie (ABBV)?
